<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00644657</url>
  </required_header>
  <id_info>
    <org_study_id>13291</org_study_id>
    <nct_id>NCT00644657</nct_id>
  </id_info>
  <brief_title>The Effect of Clopidogrel on Coated-Platelets in Patients Undergoing Cardiac Catheterization</brief_title>
  <official_title>The Effect of Clopidogrel on Coated-Platelets in Patients Undergoing Cardiac Catheterization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oklahoma</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Oklahoma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will explore the effect of clopidogrel on coated-platelets in patients who are
      given a loading dose before diagnostic catheterization or percutaneous coronary intervention.
      We hypothesis that clopidogrel will reduce the percentage of platelets that are coated and
      therefore more hypercoagulable.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Platelet activity will be determined by light transmission aggregometry at baseline, after a
      300 mg dose of clopidogrel and after the catheterization and/or angioplasty procedure. The
      change in the percentage of platelets that are coated platelets will be determined.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Percentage of Coated Platelets After the Administration of Clopidogrel in Patients Undergoing Cardiac Catheterization and/or Angioplasty</measure>
    <time_frame>24 hours after the administration of clopidotrel</time_frame>
    <description>The percentage of platelets that are collagen coated after the administration of clopidogrel.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Percentage of Coated Platelets After Coronary Angiography and/or PCI</measure>
    <time_frame>6 hrs after procedure</time_frame>
    <description>The percentage of coated platelets 24 hours after coronary angiography and/or PCI</description>
  </secondary_outcome>
  <enrollment type="Actual">27</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Chest Pain</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>All subjects will receive a 300 mg loading dose</description>
    <other_name>Plavix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients given clopidogrel loading dose before scheduled catheterization or
             percutaneous intervention

        Exclusion Criteria:

          -  Acute coronary syndrome

          -  Unable to tolerate clopidogrel
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eliot Schechter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oklahoma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Medical Center, 1F187</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104-5076</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 24, 2008</study_first_submitted>
  <study_first_submitted_qc>March 26, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2008</study_first_posted>
  <results_first_submitted>January 6, 2011</results_first_submitted>
  <results_first_submitted_qc>September 7, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 7, 2011</results_first_posted>
  <last_update_submitted>September 7, 2011</last_update_submitted>
  <last_update_submitted_qc>September 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 7, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Platelets, platelet aggregation inhibitors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Chest Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Platelet Aggregation Inhibitors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients scheduled for cardiac catheterization and possible percutaneous intervention who received a loading dose of 300 mg of clopidogrel were recruited.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Clopidogrel Loading Dose</title>
          <description>All subjects received a 300 mg loading dose of clopidogrel</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Clopidogrel</title>
          <description>All 27 subjects received a 300 mg loading dose of clopidogrel</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="27"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>The percentage of platelets that are &quot;coated-Platelets&quot; as measured by dual-agonist stimulation</title>
          <description>In each patient the percentage of platelets that are collagen coated will be measured in each patient before clopidogrel administration.</description>
          <units>percent coated platelets</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.0" spread="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Percentage of Coated Platelets After the Administration of Clopidogrel in Patients Undergoing Cardiac Catheterization and/or Angioplasty</title>
        <description>The percentage of platelets that are collagen coated after the administration of clopidogrel.</description>
        <time_frame>24 hours after the administration of clopidotrel</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clopidogrel Loading Dose</title>
            <description>All subjects received a 300 mg loading dose of clopidogrel</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Coated Platelets After the Administration of Clopidogrel in Patients Undergoing Cardiac Catheterization and/or Angioplasty</title>
          <description>The percentage of platelets that are collagen coated after the administration of clopidogrel.</description>
          <units>Percent of platelets that are coated.</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.8" spread="13.6" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percentage of Coated Platelets After Coronary Angiography and/or PCI</title>
        <description>The percentage of coated platelets 24 hours after coronary angiography and/or PCI</description>
        <time_frame>6 hrs after procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clopidogrel Loading Dose</title>
            <description>All subjects received a 300 mg loading dose of clopidogrel</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Coated Platelets After Coronary Angiography and/or PCI</title>
          <description>The percentage of coated platelets 24 hours after coronary angiography and/or PCI</description>
          <units>Percentage of platelets that are coated</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.9" spread="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Clopidogrel Loading Dose</title>
          <description>All subjects received a 300 mg loading dose of clopidogrel</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Limited to primarily Male VA population.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Eliot Schechter, MD</name_or_title>
      <organization>University of Oklahoma Health Sciences Center</organization>
      <phone>405-456-5378</phone>
      <email>eliot-schechter@ouhsc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

